The below represents select transactions

Strongbridge Biopharma

Announced: 10/31/2018 | Value: ~$182 million cash and PIPE investment plus additional undisclosed amount for inventory and sales force for three years

Exclusive financial advisor to Strongbridge Biopharma on its sale of US and Canadian rights for Macrilen to Novo Nordisk

Adynxx

Announced: 10/12/2018 | Value: Undisclosed

Exclusive financial advisor to Adynxx on its all-stock merger agreement with Alliqua BioMedical

Otsuka Pharmaceutical

Announced: 10/11/2018 | Value: $80 million

Exclusive Financial Advisor to Otsuka on its expanded collaboration agreement with Proteus to Advance Digital Medicines For Mental Health

Poxel

Announced: 08/30/2018 | Value: Upfront ~$18 million, plus additional undisclosed development and commercial milestones

Exclusive financial advisor to Poxel on its acquisition of DRX-065 and other programs from DeuteRx

Ligand Pharmaceuticals

Announced: 08/09/2018 | Value: £32.8 million

Financial advisor to Ligand Pharmaceuticals in its acquisition of Vernalis

Psyadon Pharmaceuticals

Announced: 08/08/2018 | Value: Undisclosed

Exclusive financial advisor to Psyadon Pharmaceuticals in connection with its sale to Paragon Biosciences

Protalix BioTherapeutics

Announced: 07/24/2018 | Value: Up to $805 million

Exclusive financial advisor to Protalix on its sale of the U.S. commercialization and development rights for PRX-102 to Chiesi Farmaceutici

Apollo Global Management / RCCH HealthCare Partners

Announced: 07/23/2018 | Value: $5.6 billion

MTS served as financial advisor to Apollo/RCCH on its $5.6 Billion Cash Merger with LifePoint Health (NASDAQ: LPNT)

Jazz Pharmaceuticals

Announced: 06/29/2018 | Value: $80 million

Exclusive Financial Advisor to Jazz Pharmaceuticals in its sale of Prialt to TerSera Therapeutics.

Dana-Farber Cancer Institute

Announced: 06/29/2018 | Value: Undisclosed

MTS served as exclusive financial advisor to Dana-Farber on the sale of royalty interests

Keryx Biopharmaceuticals

Announced: 06/28/2018 | Value: $1.3 billion

Financial advisor to Keryx Biopharmaceuticals in its all-stock merger with Akebia Therapeutics

University of Massachusetts Medical School

Announced: 06/22/2018 | Value: $87 million

Exclusive financial advisor to the University of Massachusetts Medical School in the structured sale of a portion of its US royalty interests in SPINRAZA

Boston Children’s Hospital

Announced: 06/19/2018 | Value: $51.5 million

Exclusive financial advisor to Boston Children’s Hospital in the structured sale of royalty interests in VONVENDI

Shionogi & Co., Ltd.

Announced: 06/13/2018 | Value: Upfront $90 million, plus additional development and commercial milestones of up to $485 million

Exclusive financial advisor to Shionogi on its strategic collaboration with Sage Therapeutics to develop and commercialize SAGE-217 in Japan, Taiwan and South Korea

Cold Spring Harbor Laboratory

Announced: 06/12/2018 | Value: Undisclosed

Exclusive financial advisor to CSHL in the structured sale of a portion of its worldwide royalty interests in SPINRAZA

Cyteir Therapeutics

Announced: 04/30/2018 | Value: $35 million

Sole placement agent

Arbutus Biopharma

Announced: 04/11/2018 | Value: Undisclosed

MTS advised the Special Committee to the Board of Directors of Arbutus on the launch of Genevant Sciences, a jointly-owned company with Roivant Sciences

pSivida

Announced: 03/28/2018 | Value: Up to $125 million

Exclusive financial advisor to pSivida in connection with its acquisition of Icon Bioscience to form EyePoint Pharmaceuticals

Ameritox

Announced: 03/05/2018 | Value: Undisclosed

Exclusive financial advisor to Ameritox in connection with its sale to Aegis Sciences Corporation, a portfolio company of Abry Partners

Addex Therapeutics

Announced: 03/05/2018 | Value: $42.6 million

Sole US placement agent for Addex Therapeutics (SWX: ADXN) in connection with a $42.6 million PIPE financing

Promise Healthcare

Announced: 02/08/2018 | Value: Undisclosed

Sale of Silver Lake Medical Center to Undisclosed Buyer

Churchill Pharmaceuticals

Announced: 01/25/2018 | Value: Undisclosed Partner

Exclusive financial advisor to Churchill Pharmaceuticals on its outlicensing of YONSA to an Undisclosed Partner

Strongbridge Biopharma

Announced: 01/17/2018 | Value: Up to $203 million

Acquisition of US and Canadian rights to MACRILEN from Aeterna Zentaris

Novozymes

Announced: 12/28/2017 | Value: Undisclosed

Exclusive financial advisor to Novozymes on the divestiture of Albumedix

ImmusanT

Announced: 11/14/2017 | Value: $40 million

Sole placement agent in Series C private financing

Ocera Therapeutics

Announced: 11/02/2017 | Value: Up to $117 million

Clinical-stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous (IV) and oral formulations

Envisia Therapeutics

Announced: 10/05/2017 | Value: $25 million plus additional undisclosed product approval milestones

Exclusive financial advisor to Envisia Therapeutics on its asset sale to Aerie Pharmaceuticals

Arbutus Biopharma

Announced: 10/02/2017 | Value: $116.4 million

Financial Advisor to Special Committee of the Board of Directors on Private Placement

Dimension Therapeutics

Announced: 10/02/2017 | Value: $171 million

Exclusive financial advisor to Dimension Therapeutics in connection with its sale to Ultragenyx Pharmaceutical

Realm Therapeutics

Announced: 09/21/2017 | Value: $26 million

Realm Therapeutics (AIM:RLM) announced an upsized $26 million private placement

Walter and Eliza Hall Institute

Announced: 07/27/2017 | Value: $325 million

Exclusive financial advisor to WEHI in the structured sale of a portion of its worldwide royalty interests in venetoclax

Physicians Dialysis and GMF Capital

Announced: 05/01/2017 | Value: Undisclosed

Exclusive financial and debt advisor to Physicians Dialysis and GMF Capital in connection with acquisition of assets from DaVita

Zymeworks

Announced: 04/27/2017 | Value: $59 million

Financial advisor to Zymeworks in connection with its IPO

Verona Pharma plc

Announced: 04/26/2017 | Value: $80 million

Financial advisor to Verona Pharma in connection with its U.S. IPO

Caladrius Biosciences

Announced: 03/16/2017 | Value: $75 million upfront, plus $5 million additional potential sales milestone payment

Exclusive financial advisor to Caladrius Biosciences on the sale of its remaining 80.1% equity stake in its PCT, LLC subsidiary

Otsuka Pharmaceutical

Announced: 03/02/2017 | Value: $100 million upfront, plus up to $150mm in development & regulatory milestones, plus additional potential sales milestone payments

Exclusive financial advisor to Otsuka Pharmaceutical Co., Ltd. on its acquisition of Neurovance, Inc.

Arizona Center for Cancer Care

Announced: 01/30/2017 | Value: Undisclosed

Exclusive financial advisor to AZCCC in connection with its Joint Venture with HonorHealth

CoLucid Pharmaceuticals

Announced: 01/18/2017 | Value: $960 million

Exclusive sell-side advisor to CoLucid Pharmaceuticals on its sale to Eli Lilly and Company

Ipsen

Announced: 01/08/2017 | Value: $575 million plus up to $450 million in contingent payments

Exclusive financial advisor to Ipsen on its acquisition of Onivyde from Merrimack Pharmaceuticals

OncoGenex Pharmaceuticals

Announced: 01/05/2017 | Value: Undisclosed

Exclusive financial advisor to OncoGenex Pharmaceuticals on its all-stock merger agreement with Achieve Life Science

Shire plc (NASDAQ:SHPG)

Announced: 01/04/2017 | Value: Undisclosed

Exclusive financial advisor to Shire on the spin-out of its MRT platform to RaNA Therapeutics

Universal American

Announced: 11/17/2016 | Value: $800 million

MTS advised Universal American on its sale to WellCare Health Plans

Ocular Technologies (an Auven Therapeutics portfolio company)

Announced: 10/26/2016 | Value: $40 million plus contingent payments

Exclusive financial advisor to Auven Therapeutics in the sale of Seciera, a Phase 3 clinical asset for the treatment of dry eye disease

Horizon Pharma Plc

Announced: 09/12/2016 | Value: $800 million

Lead financial advisor to Horizon Pharma Plc on its acquisition of Raptor Pharmaceutical

PathGroup

Announced: 08/01/2016 | Value: Undisclosed

Exclusive financial advisor to PathGroup in connection with its sale to Pritzker Group Private Capital

Dana-Farber Cancer Institute

Announced: 07/29/2016 | Value: $168 million

Long-term exclusive financial advisor to DFCI in the structured sale of a portion of its royalty interests in certain PD-L1 products and product candidates

Medical Research Council Technology

Announced: 07/08/2016 | Value: $150 million

Exclusive financial advisor to MRCT in the structured sale of a portion of its worldwide royalty interests in KEYTRUDA

Bloom Health

Announced: 07/06/2016 | Value: Undisclosed

Sole advisor to Bloom Health on its sale to Empyrean Benefit Solutions

Verona Pharma

Announced: 06/17/2016 | Value: $63.3 million

Sole US placement agent for Verona Pharma in connection with raising $63.3 million in a PIPE financing

Celator Pharmaceuticals

Announced: 05/31/2016 | Value: $1.5 billion

Exclusive financial advisor to Celator in connection with its sale to Jazz Pharmaceuticals

Synta Pharmaceuticals

Announced: 04/14/2016 | Value: Undisclosed

Financial Advisor to Synta Pharmaceuticals on its all-stock merger agreement with Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

Announced: 04/14/2016 | Value: Undisclosed

Strategic Advisor to Madrigal Pharmaceuticals on its all-stock merger agreement with Synta Pharmaceuticals

Starmount

Announced: 04/04/2016 | Value: $127 million

Exclusive financial advisor to Starmount in connection with its sale to Unum Group (NYSE: UNM)

Celator Pharmaceuticals

Announced: 03/23/2016 | Value: $44 million

Financial advisor to Celator Pharmaceuticals (NASDAQ:CPXX) on its $43.7 Million Public Offering

Caladrius Biosciences

Announced: 03/14/2016 | Value: $25 million

Exclusive financial advisor to Caladrius Biosciences on its Strategic Global Collaboration and Asia License Agreement with Hitachi Chemical (19.9% Equity Stake for $19.4 Million and $5.6 Million Upfront)

Signature Hospice and Home Health

Announced: 03/09/2016 | Value: $84 million

Exclusive financial advisor to Genesis Healthcare (NYSE: GEN) on the sale of its Signature Hospice and Home Health operations to Hospice Compassus

Laurel Health Care Company

Announced: 02/02/2016 | Value: Undisclosed

Sale of real estate assets to Omega Healthcare Investors as well as the sale of operations to Ciena Healthcare

Tarveda Therapeutics (formerly Blend Therapeutics)

Announced: 01/27/2016 | Value: $38 million

Sole placement agent for Tarveda Therapeutics on its $38 Million Private Placement

Acorda Therapeutics

Announced: 01/19/2016 | Value: $363 million

Financial advisor to Acorda Therapeutics on the acquisition of Biotie Therapies

Aprecia Pharmaceuticals

Announced: 01/14/2016 | Value: $50 million

Sole placement agent for Aprecia Pharmaceuticals on its $50 Million Private Placement

Zymeworks

Announced: 01/08/2016 | Value: $62 million

Lead placement agent for Zymeworks in connection with raising $61.5 million of Series A financing

Diffusion Pharmaceuticals LLC

Announced: 12/15/2015 | Value: Undisclosed

Exclusive financial advisor to Diffusion Pharmaceuticals on its merger with RestorGenex Corporation

Velicept Therapeutics

Announced: 11/24/2015 | Value: $20 million

Sole placement agent for Velicept Therapeutics on its $20 million Private Placement

Examination Management Services Inc.

Announced: 11/03/2015 | Value: Undisclosed

Exclusive financial advisor to EMSI in connection with its sale to Beecken Petty O’Keefe

StrataDx

Announced: 10/01/2015 | Value: Undisclosed

Exclusive financial advisor to StrataDx in connection with its sale to Dermatopathology Experts

Health Diagnostic Laboratory

Announced: 09/11/2015 | Value: $37.1 million

Financial advisor to HDL in its Section 363 sale to True Health Diagnostics

Tripex Pharmaceuticals

Announced: 08/20/2015 | Value: $418.4 million

Exclusive advisor for Tripex in connection with its sale of Quinsair to Raptor Pharmaceuticals

Celsus Therapeutics

Announced: 08/18/2015 | Value: $75 million

Placement agent for Celsus in connection with raising $75 million in a PIPE financing

TeamHealth

Announced: 08/04/2015 | Value: $1.6 billion

Financial advisor to TeamHealth on its acquisition of IPC Healthcare

Celsus Therapeutics

Announced: 07/13/2015 | Value: Undisclosed

Financial advisor to Celsus Therapeutics on its merger with Volution Immuno Pharmaceuticals

ARCA biopharma

Announced: 06/11/2015 | Value: $37 million

Sole placement agent for ARCA biopharma in connection with raising $37 million in a PIPE financing

University of Maryland Medical System

Announced: 05/14/2015 | Value: Not Disclosed

Exclusive advisor for the University of Maryland Medical System in connection with its acquisition of Riverside Health

Baxter International Inc.

Announced: 05/12/2015 | Value: $900 million

Financial advisor to Baxter International Inc. on its acquisition of Oncaspar Portfolio from Sigma-Tau Finanziaria S.p.A

ImmunoGen, Inc.

Announced: 03/30/2015 | Value: $200 million

Exclusive financial advisor to ImmunoGen, Inc. in the structured sale of a portion of its worldwide royalty interests in Kadcyla

Champions Oncology

Announced: 03/12/2015 | Value: $14 million

Sole placement agent for Champions Oncology in connection with raising $14 million in a PIPE financing

TRACON Pharmaceuticals, Inc.

Announced: 01/29/2015 | Value: $41 million

Financial advisor to TRACON Pharmaceuticals, Inc. in connection with its Initial Public Offering

Regado Biosciences

Announced: 01/14/2015 | Value: Not Disclosed

Financial advisor to Regado Biosciences on its merger with Tobira Therapeutics

Otsuka Pharmaceutical

Announced: 12/02/2014 | Value: $3.54 billion

Financial advisor to Otsuka Pharmaceutical Co., Ltd. on its acquisition of Avanir Pharmaceuticals, Inc.

Community Health Systems

Announced: 11/07/2014 | Value: Not Disclosed

Exclusive financial advisor to Community Health Systems on its divestiture of Riverview Regional Medical Center to Prime Healthcare Services

GE Capital, Healthcare Financial Services

Announced: 11/05/2014 | Value: $305 million

Exclusive financial advisor to GE Capital, Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Aviv REIT

Paul Capital

Announced: 10/17/2014 | Value: Not Disclosed

Exclusive financial advisor to Paul Capital on the secondary sale of royalty streams generated by seven pharmaceuticals

Community Health Systems

Announced: 10/13/2014 | Value: Not Disclosed

Exclusive financial advisor to Community Health Systems on its divestiture of Carolina Pines Regional Medical Center to Capella Healthcare

WellSpring Pharmaceutical

Announced: 10/03/2014 | Value: Not Disclosed

Exclusive financial advisor to WellSpring Pharmaceutical Corporation on the sale of its Prescription Pharmaceutical Business

Acorda Therapeutics

Announced: 09/24/2014 | Value: $525 million

Financial advisor to Acorda Therapeutics on the acquisition of Civitas Therapeutics

TRACON Pharmaceuticals

Announced: 09/22/2014 | Value: $27 million

Lead placement agent for Tracon in connection with raising $27.0 million of Series B financing

Aerie Pharmaceuticals, Inc.

Announced: 09/09/2014 | Value: $125 million

Exclusive financial advisor to Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to enter into a $125m secured convertible debt facility agreement with Deerfield Capital Management for continued development of product pipeline (Rhopressa™ and Roclatan™), general corporate purposes, and strategic growth opportunities

Skilled Healthcare Group

Announced: 08/18/2014 | Value: NA

Exclusive financial advisor to Skilled Healthcare Group Inc. (NYSE:SKH) on its merger with Genesis HealthCare

AesRx

Announced: 07/09/2014 | Value: Not Disclosed

Exclusive financial advisor to AesRx, LLC on its sale to Baxter International Inc.

Nicox

Announced: 07/02/2014 | Value: Up to $120 million

Exclusive financial advisor to Nicox, SA on its acquisition of Aciex Therapeutics, Inc.

Vistria

Announced: 06/24/2014 | Value: Not Disclosed

Financial advisor to Vistria on its acquisition of Angel MedFlight

Cymetrix

Announced: 05/14/2014 | Value: Up to $100 million

Financial advisor to Cymetrix on its sale to Navigant

Alder Biopharmaceuticals Inc

Announced: 05/08/2014 | Value: $80 million

Financial advisor to Alder Biopharmaceuticals Inc in connection with its Initial Public Offering

Corrona

Announced: 04/17/2014 | Value: Not Disclosed

MTS acted as financial advisor on the growth recapitalization of Corrona

Kaléo

Announced: 04/07/2014 | Value: $150 million

Exclusive financial advisor to kaléo to enter into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaléo to support commercialization of EVZIO™ (naloxone hydrochloride injection) and development of key pipeline products

Promise Healthcare

Announced: 04/02/2014 | Value: Not Disclosed

Financial advisor to Promise Healthcare, Inc. on its acquisition of six healthcare facilities including four long-term acute care hospitals and two skilled nursing facilities

Oxygen Biotherapeutics

Announced: 03/18/2014 | Value: $59.8 million

MTS served as underwriter for the transaction and led efforts with institutional investors participating in the offering

Promise Healthcare

Announced: 03/17/2014 | Value: Not Disclosed

Financial advisor to Promise Healthcare, Inc. on its restructuring

NuPathe Inc.

Announced: 01/21/2014 | Value: $268 million

Financial advisor to NuPathe Inc. on its sale to Teva Pharmaceutical Industries.

Iroko Pharmaceuticals

Announced: 11/21/2013 | Value: $75 million

Exclusive financial advisor to Iroko to enter into a $75m debt facility agreement to support general business operations and the launch of Zorvolex (diclofenac)

Almost Family, Inc.

Announced: 11/5/2013 | Value: $75.5 million

Financial advisor to Almost Family, Inc. on its acquisition of SunCrest Healthcare

Miraca Life Sciences

Announced: 10/23/2013 | Value: Not Disclosed

Financial advisor to Miraca Life Sciences on its acquisition of PLUS Diagnostics

La Jolla Pharmaceutical

Announced: 09/25/2013 | Value: $10 million

Sole placement agent for La Jolla Pharmaceutical Company in connection with raising $10.0 million through common and preferred shares

Celsus Therapeutics

Announced: 09/19/2013 | Value: $12.5 million

Placement agent for Celsus Therapeutics in connection with raising $12.5 million through common shares

QuantiaMD

Announced: 9/3/2013 | Value: $10 million

Sole placement agent for Quantia Communications, Inc. on its $10 million Private Placement

Acorda Therapeutics

Announced: 7/9/2013 | Value: Not Disclosed

Financial advisor to Acorda Therapeutics on the acquisition of Qutenza™ and NP-1998 from NeurogesX

University of Pennsylvania

Announced: 6/25/2013 | Value: $55 million

Exclusive financial advisor to University of Pennsylvania in the structured sale of a portion of its worldwide royalty interests in Juxtapid

Laboratory Partners

Announced: 6/3/2013 | Value: Not Disclosed

Financial advisor to Laboratory Partners on the sale of its physician outreach business

AmeriHealth Caritas

Announced: 5/1/2013 | Value: Not Disclosed

Financial advisor to AmeriHealth Caritas on its acquisition of DC Chartered Health Plan assets

RXi Pharmaceuticals Corporation

Announced: 3/1/2013 | Value: $16.4 million

Sole placement agent for RXI Pharmaceuticals Corp. in connection with raising $16.4 million through the sale of common shares

Progenics Pharmaceuticals

Announced: 1/22/2013 | Value: Up to $105 million

Financial advisor to Progenics Pharmaceuticals, Inc on its acquisition of Molecular Insight Pharmaceuticals

TractManager Inc.

Announced: 1/7/2013 | Value: Not Disclosed

Exclusive financial advisor to TractManager, Inc. in connection with the majority recapitization investment by Arsenal Capital Partners

Florida Clinical Laboratory

Announced: 12/31/2012 | Value: Not Disclosed

Exclusive financial advisor to Florida Clinical Laboratory on its sale to Bio-Reference Laboratories, Inc.

BioScrip

Announced: 12/13/2012 | Value: $70 million

Financial advisor to BioScrip Inc. on its acquisition of HomeChoice Partners, Inc. from DaVita HealthCare Partners

GE Capital, Healthcare Financial Services

Announced: 12/1/2012 | Value: Not Disclosed

Exclusive financial advisor to GE Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Formation Capital

MethylGene

Announced: 11/21/2012 | Value: $26 million

Acted as a placement agent for MethylGene in connection with raising $26MM in a PIPE financing

NuPathe

Announced: 10/23/2012 | Value: $28 million

Co-placement agent for NuPathe, Inc. in connection with raising $28 million in a PIPE financing

Fibrocell Science

Announced: 10/8/2012 | Value: $45 million

Lead placement agent for Fibrocell Science, Inc. in connection with raising $45 million in a PIPE financing. Strategic Advisor to Fibrocell Science, Inc on its strategic collaboration with Intrexon

Jazz Pharmaceuticals

Announced: 9/6/2012 | Value: $95 Million

Exclusive financial advisor to Jazz Pharmaceuticals on the sale of its Women’s Health Business to Meda AB

Idenix Pharmaceuticals

Announced: 8/2/2012 | Value: $176 million

Financial advisor to Idenix Pharmaceuticals, Inc. on its $176 million follow-on public offering of common stock

BioScrip

Announced: 7/31/2012 | Value: $41 million

Financial advisor to BioScrip Inc. on its acquisition of InfuScience from Cressey & Company

Not Disclosed

Announced: 6/30/2012 | Value: Not Disclosed

Financial advisor to Undisclosed Public Buyer on its acquisition of Healthy Circles

Sun Healthcare

Announced: 6/20/2012 | Value: $275 million

Exclusive financial advisor to Sun Healthcare on its sale to Genesis Healthcare

Lumeris Corporation

Announced: 2/14/2012 | Value: Not Disclosed

Financial advisor to Lumeris Corp. on its acqusition of NaviNet in partnership with Highmark, Horizon Blue Cross Blue Shield of New Jersey and Independence Blue Cross

BioScrip

Announced: 2/2/2012 | Value: $285 million

Financial advisor to BioScrip Inc. on its sale of its community specialty pharmacies and centralized specialty and mail service pharmacy businesses to Walgreens

Idenix Pharmaceuticals

Announced: 11/16/2011 | Value: $61.1 million

Financial advisor to Idenix Pharmaceuticals, Inc. on its $61 million follow-on public offering of common stock

A.P. Pharma

Announced: 6/29/2011 | Value: $24 million

Sole placement agent for AP Pharma in connection with raising $24 million in a PIPE financing

Highmark

Announced: 6/28/2011 | Value: $1.3 billion

Financial advisor to Highmark Inc. in connection with its acquisition of West Penn Allegheny Health System

Trimeris

Announced: 6/13/2011 | Value: $285 million

Exclusive financial advisor to Trimeris Inc. on its reverse merger with Synageva BioPharma Corp

Advanced Vision Research

Announced: 5/3/2011 | Value: $26 million

Exclusive financial advisor to Advanced Vision Research on its sale to Akorn, Inc.

MethylGene

Announced: 3/24/2011 | Value: $35 million

Sole placement agent for MethylGene in connection with raising $35 million in a PIPE financing

Intercell AG

Announced: 2/23/2011 | Value: $45.5 million

Financial advisor to Intercell AG related to the issuance of senior unsecured convertible notes

Sol Amor Hospice

Announced: 1/3/2011 | Value: Not Disclosed

Exclusive financial advisor to Sun Healthcare and its subsidiary SolAmor Hospice on its acquisition of Countryside Hospice

Acadia Pharmaceuticals

Announced: 1/1/2011 | Value: $15 million

Co-placement agent for Acadia Pharmaceuticals Inc. in connection with raising $15 million in a PIPE financing

Aastrom Biosciences

Announced: 12/10/2010 | Value: $22.5 million

Financial advisor to Aastrom Biosciences for its $22.5 million follow-on offering

Neurologix

Announced: 12/6/2010 | Value: $7 million

Lead placement agent for Neurologix, Inc. in connection with raising $7 million in convertible debt

Reata Pharmaceuticals

Announced: 9/23/2010 | Value: $450 million

Strategic advisor to Reata Pharmaceuticals in its landmark ex-US partnership with Abbott Labs

Sun Healthcare

Announced: 8/13/2010 | Value: $238 million

Financial advisor to Sun Healthcare on its equity offering in connection with its restructuring and spinof of its real estate assets

Solstice Neurosciences

Announced: 8/13/2010 | Value: Not Disclosed

Exclusive financial advisor to Solstice Neurosciences, LLC on its sale to US WorldMeds

Trubion Pharmaceuticals

Announced: 8/12/2010 | Value: Up to $140 million

Financial advisor to Trubion Pharmaceuticals on its sale to Emergent Biosolutions

NuPathe

Announced: 8/6/2010 | Value: $50 million

Financial advisor to NuPathe, Inc in connection with its Initial Public Offering

Westcliff Medical Laboratories

Announced: 7/18/2010 | Value: $74 million

Exclusive financial advisor to Westcliff Medical Laboratories on its restructuring and sale to Laboratory Corporation of America

Accolade

Announced: 7/1/2010 | Value: $17 million

Sole placement agent for Accolade LLC on its $17 million Private Placement

Sun Healthcare

Announced: 5/24/2010 | Value: $1.6 billion

Financial advisor to Sun Healthcare on its spin of real estate assets into separately traded Sabra Health Care REIT (SBRA)

Inhibitex

Announced: 10/26/2009 | Value: $23 million

Exclusive placement agent for Inhibitex, Inc. in connection with raising $23 million in a PIPE financing

Threshold Pharmaceuticals

Announced: 10/6/2009 | Value: $35 million

Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $35 million in a PIPE financing

Neurogen Corporation

Announced: 8/24/2009 | Value: $11 - 27 million

Exclusive financial advisor to Neurogen Corporation on its Sale to Ligand Pharmaceuticals Incorporated

Reata Pharmaceuticals

Announced: 3/27/2009 | Value: $32 million

Sole placement agent for Reata Pharmaceuticals, Inc on its $32 million Private Placement

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2009 | Value: $37 million

Divestiture of dental insurance business of a not-for-profit insurer

GTC Biotherapeutics

Announced: 11/3/2008 | Value: $15 million

Financial advisor to GTC Biotherapeutics, Inc on its $15 million Convertible Debt financing

Oscient Pharmaceuticals

Announced: 10/21/2008 | Value: $213 million

Dealer manager in connection with debt restructuring and recapitalization

Link Medicine

Announced: 9/30/2008 | Value: $40 million

Sole placement agent for Link Medicine Corporation on its $40 million Private Placement

Threshold Pharmaceuticals

Announced: 7/10/2008 | Value: $18 million

Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $18 million in a PIPE financing

My Innerview

Announced: 2008 | Value: Not Disclosed

Exclusive financial advisor in connection with its sale to National Research Corporation (NRCI)

Coram

Announced: 10/12/2007 | Value: $350 million

Exclusive financial advisor in connection with its sale to Apria (AHG)

Universal American (UAM)

Announced: 2007 | Value: $630 million

Financial advisor to priviate equity consortium in connection with its investment to fund the acquisition of MemberHealth

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2007 | Value: $125 million

Acquisition of CompWest

Coram

Announced: 2007 | Value: Not Disclosed

Sale of Canadian infusion portfolio

Sun Healthcare Group

Announced: 12/1/2006 | Value: $19 million

Exclusive financial advisor to Sun Healthcare on its sale of SunPlus Home Health Services to AccentCare Home Health

Sun Healthcare Group

Announced: 10/19/2006 | Value: $625 million

Exclusive financial advisor to Sun Healthcare on its acquisition of Harborside Healthcare

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2006 | Value: $240 million

Acquisition of M-Care

Coram

Announced: 2006 | Value: Not Disclosed

Sale of home infusion portfolio

Pacificare (PHSY)

Announced: 2005 | Value: $9 billion

Sale to UnitedHealthcare (UHG)

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2005 | Value: Not Disclosed

Sale of PPO Business

Sun Healthcare Group

Announced: 5/19/2005 | Value: $246 million

Financial advisor to Sun Healthcare on its acquisition of Peak Medical

Pacificare (PHSY)

Announced: 2005 | Value: Not Disclosed

Acquisition of Pacific Life’s group health insurance business

PresGar Companies

Announced: 2004 | Value: $135 million

Restructuring

PresGar Companies

Announced: 2004 | Value: Not Disclosed

Sale of imaging center portfolio to undislosed buyer

Pacificare (PHSY)

Announced: 2004 | Value: $532 million

Acquisition of American Medical Security Group (AMZ)

Sloans Lake

Announced: 2004 | Value: $45 million

Sale to undiclosed financial buyer

Sun Healthcare Group

Announced: 2/1/2004 | Value: $1.4 billion

Exclusive financial advisor to Sun Healthcare Group on its restructuring

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2004 | Value: $200 million

Structured Financing

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2003 | Value: $150 million

Divestiture

Sun Healthcare Group

Announced: 9/1/2003 | Value: $75 million

Financial advisor to Sun Healthcare on its Senior Debt Financing

Sun Healthcare Group

Announced: 6/17/2003 | Value: $90 million

Exclusive financial advisor to Sun Healthcare on its sale of SunScript Pharmacy Services to Omnicare

Pacificare (PHSY)

Announced: 2002 | Value: $200 million

Advisor to PacifiCare in connection with its High-Yield Financing

The Mentor Network

Announced: 2001 | Value: $126 million

Sale to Madison Dearborn Capital Partners

Magellan Health Services (MGLN)

Announced: 2001 | Value: $250 million

Debt Financing

Schein Pharmaceuticals (SHP)

Announced: 2000 | Value: $1.4 billion

Sale to Watson Pharmaceuticals (WPI)